News

The financing was co-led by Arix Bioscience and New Leaf Venture Partners. Mark Chin, Investment Manager at Arix, and Ron Hunt, Managing Director at New Leaf, will join

The committee has recommended the approval based on its assessment of the totality of evidence, comprising of showing comparable efficacy and safety of biosimilar epoetin alfa to its

The pre-specified primary endpoint was the change-from-baseline between the placebo and active groups in the Yale Global Tic Severity Scale (YGTSS) at Week 6 in the intent-to-treat (ITT)

Under the terms of the agreement, ImmunoGen received a $25 million upfront payment for IMGN529/Debio 1562 and is entitled to a $5 million milestone payment to be paid

The American biotech company said that its DNA vaccine combination had produced some of the highest overall levels of immune response rates ever recorded in the history of

The American biotech company said that its DNA vaccine combination had produced some of the highest overall levels of immune response rates ever recorded in the history of

This is the first time the agency has approved a cancer treatment based on a common biomarker rather than the location in the body where the tumor originated.

This sets out the Competition and Markets Authority’s (CMA) provisional decision that MSD operated an anti-competitive discount scheme for its medicine Remicade. Remicade is the brand name for

Actemra is the first therapy approved by the FDA for the treatment of adult patients with GCA. This is the sixth FDA approval for Actemra since the medicine